Efficacy and safety of selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors in FGFR-altered urothelial carcinoma

Efficacy and safety of selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors in FGFR-altered urothelial carcinoma

Fibroblast growth factor receptor (FGFR) alteration is one of the common driver alterations in urothelial carcinoma (UC). FGFR alterations contribute to anti-tumor immunity inhibition and are associated with attenuated response to immune checkpoint inhibitor (ICI) or chemotherapy. Selective pan-FGFR...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yuxuan Song, Yiqing Du, Shan Jiang, Yun Peng, Xing Luo, Tao Xu
Format:	Article
Language:	English
Published:	Elsevier 2025-01-01
Series:	Pharmacological Research
Subjects:	Urothelial carcinoma Targeted cancer therapy Fibroblast growth factor receptor Immune checkpoint inhibitor
Online Access:	http://www.sciencedirect.com/science/article/pii/S1043661824004882
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Novel combination therapy for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma: a systematic review and network meta-analysis
by: Takafumi Yanagisawa, et al.
Published: (2025-02-01)

The molecular mechanism of gemcitabine in inhibiting the HIF-1α/VEGFB/FGF2/FGFR1 signaling pathway for ovarian cancer treatment
by: Liangliang Wang, et al.
Published: (2025-01-01)

Target trial emulation to evaluate the effect of immune-related adverse events on outcomes in metastatic urothelial cancer
by: Renate Pichler, et al.
Published: (2024-12-01)

Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison
by: Wei Chen, et al.
Published: (2025-01-01)

Cell-free expression and SMA copolymer encapsulation of a functional receptor tyrosine kinase disease variant, FGFR3-TACC3
by: Alexander J. D. Snow, et al.
Published: (2025-01-01)

Therapeutic effect of selective interleukin-2-inducible tyrosine kinase inhibitor in orbital fibroblasts from patients with Graves’ orbitopathy
by: Yeonjung Yoon, et al.
Published: (2024-09-01)

Endothelin receptor antagonists (ERAs) can potentially be used as therapeutic drugs to reduce hypertension caused by small molecule tyrosine kinase inhibitors (TKIs)
by: Qingjian He, et al.
Published: (2025-01-01)

Advances in Therapy for Urothelial and Non-Urothelial Subtype Histologies of Advanced Bladder Cancer: From Etiology to Current Development
by: Whi-An Kwon, et al.
Published: (2025-01-01)

Analysis of Gene Expression in Human Dermal Fibroblasts Treated with Senescence-Modulating COX Inhibitors
by: Jeong A. Han, et al.
Published: (2017-06-01)

Correlation of HER2 expression and clinicopathological characteristics in patients with urothelial carcinoma in China
by: WANG Shanshan, YE Dingwei, YANG Li, CHENG Fan, YANG Tiejun, ZHANG Xiaoping, YU Zhixian, ZHANG Qingyun, YANG Yong
Published: (2024-11-01)

Fibroblast Growth Factor Receptor 3 (FGFR3)–Analyses of the S249C Mutation and Protein Expression in Primary Cervical Carcinomas
by: Haiyan Dai, et al.
Published: (2001-01-01)

Subacute parkinsonism induced by immune checkpoint inhibitors
by: Lénia Silva, et al.
Published: (2024-12-01)

Papillary urothelial neoplasm of low malignant potential with osseous metaplasia in a 19-year-old chronic smoker: A case report with review of literature
by: Rakesh K. Gupta, et al.
Published: (2022-05-01)

Spleen tyrosine kinase inhibitors disrupt human neutrophil swarming and antifungal functions
by: Alex Hopke, et al.
Published: (2025-01-01)

Plasmacytoid urothelial carcinoma with duodenal metastasis—A rare tumor with unusual site of metastasis with grim outcome
by: Aparna Chenniappan, et al.
Published: (2023-01-01)

Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics
by: B.E. Nelson, et al.
Published: (2025-03-01)

Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
by: Evan Pisick, et al.
Published: (2004-01-01)

Roles of retinoic acid-related orphan receptor α in high glucose-induced cardiac fibroblasts proliferation
by: Wenqing San, et al.
Published: (2025-01-01)

Sulfatase modifying factor 2 as a predictive biomarker for urothelial carcinoma
by: Wei-Ting Kuo, et al.
Published: (2025-02-01)

Repurposing of Metformin to Improve Survival Outcomes in Patients With Upper Tract Urothelial Carcinoma
by: Hsiang Ying Lee, et al.
Published: (2025-01-01)

Programmed cell death 1 inhibitor alone or combined with chemotherapy for patients with locally advanced or metastatic urothelial carcinoma: a single-center experience
by: Xing Huang, et al.
Published: (2024-12-01)

Epidermal Growth Factor Receptor Exon 19 Deletion Subtypes Do Not Influence Survival Outcomes Following First-line Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitors in Advanced Nonsmall Cell Lung Cancer Patients
by: Yan-Jei Tang, et al.
Published: (2024-01-01)

Cerebrovascular stenosis related to tyrosine kinase inhibitor for chronic myeloid leukemia: two illustrative cases
by: Nozomi Sasaki, et al.
Published: (2025-01-01)

Immune checkpoint inhibitors-related thyroid dysfunction: influencing factor analysis, prediction model development, and management strategy proposal
by: Xinya Li, et al.
Published: (2024-11-01)

The tyrosine kinase inhibitor lenvatinib is oxidized by rat cytochromes P450 and affects their expression in rat liver
by: Indra Radek, et al.
Published: (2024-09-01)

De Novo Heterozygous Mutation in FGFR2 Causing Type II Pfeiffer Syndrome
by: Rafat Mosalli, et al.
Published: (2022-01-01)

FGFR antagonists restore defective mandibular bone repair in a mouse model of osteochondrodysplasia
by: Anne Morice, et al.
Published: (2025-01-01)

The Role of the Key Differentially Mutated Gene FGFR3 in the Immune Microenvironment of Bladder Cancer
by: Jun Jiang, et al.
Published: (2022-01-01)

Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in South Africa
by: Rochelle Woudberg, et al.
Published: (2025-01-01)

Dramatic Response to Enfortumab Vedotin in Soft-tissue Metastases from Urothelial Carcinoma: A Case Report
by: Ming-Hsuan Wu, et al.
Published: (2024-12-01)

Protein kinase inhibitors as targeted therapy for glioblastoma: a meta-analysis of randomized controlled clinical trials
by: José Pinto-Fraga, et al.
Published: (2025-02-01)

The Evaluation of CD10 and HER2 Immunohistochemical Markers in Urothelial Carcinoma of Urinary Bladder
by: Khalid W. Abdulfattah Khattab, et al.
Published: (2024-12-01)

Papillary Urothelial Neoplasia with Low Malignant Potential (PUNLMP) in a 9-year-old Child: A Case Report and Review of Literature
by: Abbas Al Bazzal, et al.
Published: (2025-01-01)

Hypochondroplasia, Acanthosis Nigricans, and Insulin Resistance in a Child with FGFR3 Mutation: Is It Just an Association?
by: Manal Mustafa, et al.
Published: (2014-01-01)

Reduced p63 expression is linked to unfavourable prognosis in muscle‐invasive urothelial carcinoma of the bladder
by: Kira Furlano, et al.
Published: (2024-11-01)

Characteristics, Incidence, and Management of Immune Checkpoint Inhibitors Related Cardiovascular Adverse Events in Real-World Practice-A Retrospective Study in Chinese Han Population
by: Wang RH, et al.
Published: (2025-02-01)

Fibroblastic rheumatism
by: Jyoti Ranjan Parida
Published: (2017-01-01)

Pathological features and immunohistochemical characteristics of clear cell (glycogen-rich) urothelial carcinoma: a case report and systematic review of the literature
by: Weiming Wang, et al.
Published: (2025-02-01)

Resistance mechanisms to immune checkpoint inhibitors: updated insights
by: Besan H. Alsaafeen, et al.
Published: (2025-01-01)

Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study
by: Ping Zhou, et al.
Published: (2024-12-01)